Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

ABSTRACT:

SUBMITTER: Munro APS 

PROVIDER: S-EPMC8639161 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature